French Urologist to Top TV News Mag: Propecia is a potentially dangerous drug—’I even told my brother-in-law to stop taking it’

February 10, 2019

Dear Friends:

Vive la France!

This time we call your attention to a PFS report last week on 66 Minutes, which models itself after the iconic American news magazine 60 Minutes and boasts a Sunday-evening audience of two million viewers.

The 14-minute segment, titled Is This Hair-loss Drug Dangerous? (English-subtitled version here), features an interview with François Desgrandchamps, chairman of the Urology Department at Saint-Louis Hospital in Paris.

“I think this is a potentially dangerous drug. Twenty percent of men who take Propecia see their sexual function diminish,” he tells producer Paul Gasnier.

“I even told my brother-in-law to stop taking it,” adds Dr. Desgrandchamps, who’s among the PFS Foundation’s global team of Medical Professionals offering support to PFS patients.

The 66 Minutes story comes on the heels of two important PFS news events:

“Last Friday, the esteemed medical journal Préscrire published its seventh annual list of drugs that are more harmful than helpful. Among them is Propecia,” host Xavier de Moulins reports at the top of the program.

Later in the show, Gasnier notes that “the mass of side-effects reports [about finasteride] is worrying ANSM, the French National Agency for the Security of Medication… In October 2017, it ordered all manufactures selling the drug to add psychological troubles to its insert as a possible side effect.”

And of course, as we recently told you, ANSM dispatched a second finasteride alert (Regulatory Update: France’s FDA-Equivalent Agency Reissues Finasteride Warning) in a letter to more than 100,000 health professionals on Feb. 1 of this year.

Also interviewed on the 66 Minutes segment are PFS Foundation CEO John Santmann, whose PFS-afflicted son Randy took his own life in 2008, and Sylviane Mathieu, whose PFS-afflicted son Romain took his own life in 2016. Mathieu has since founded Aide aux Victimes du Finastéride (AVFIN) to promote PFS awareness in France. (And is doing a superb job at it.)

“On average, we get a call a day, from all over the world, from the United States, Mexico, Latin America, Europe, Asia,” says Santmann. “When they call, they’re desperate—and frankly, we didn’t expect to become a suicide hotline.”

“We have to tell people, we must cry out, we must do something, we need people to know that this drug can—not in all cases, but in some—drive someone to his death,” says Mathieu.

Anyone living in the US who suffers from PFS should report his symptoms to the US Food and Drug Administration; anyone living outside the US who suffers from PFS should report his symptoms to the US Food and Drug Administration as well as to his national drug-regulatory agency, as directed on our Report Your Side Effects page.

Finally, If you or a loved one are suffering from PFS, and feeling depressed or unstable, please don’t hesitate to contact the PFS Foundation as soon as possible via our Patient Support hotline:

Thank you.

Related News

France’s Le Monde to 300,000 Readers: Finasteride Users Beware (Feb. 1, 2019)

Regulatory Update: Germany’s FDA Equivalent Issues ‘Red Hand Letter’ on Finasteride ADRs (July 6, 2018)

French Warning of Propecia-Induced Depression and Suicidal Ideation Prompts Wave of Media Attention (Dec. 19, 2017)

Korea Mandates Propecia Label Change Based on Reports of Depression and Suicidal Ideation (July 15, 2017)

European Medicines Agency Recommends Adding Depression and Suicidal Ideation to Finasteride Label (April 10, 2017)